Abstract 1200P
Background
Both CBZ and TMZ have already shown clinical efficacy in patients (pts) with NENs when used in monotherapy. Preclinical evidence demonstrated that downregulation of c-MET increases the sensitivity of glioblastoma cell lines to TMZ, and we hypothesized that CBZ could enhance the clinical efficacy of TMZ against NENs by inhibiting c-MET. The Cabotem trial aims at evaluating the efficacy and safety of CBZ in combination with TMZ as a treatment in lung and GEP-NENs progressive to SSAs, everolimus, sunitinib or PRRT.
Methods
This is a phase II, open-label, single-arm, multicentre study. Thirty-five pts were treated with CBZ (40 mg per os daily continuously) and TMZ 100 mg/m2/day (one week on/one week off). The primary endpoint was overall response rate (ORR) assessed by RECIST v1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and 1-year OS.
Results
Of the 33 patients enrolled (M: 14, F: 19; pancreas:12; GI: 9; Lung: 8; UNK: 4), 25 are currently evaluable for response. After a median follow-up of 6 months, an ORR of 12% was recorded, with a clinical benefit rate (CR+PR+SD) of 72%. Ten patients prematurely discontinued the treatment (median: 3 months) due to severe adverse events (AEs). The most common G3/G4 treatment-related AEs were thrombocytopenia, palmar/plantar erythrodysesthesia, nausea, vomiting, appetite loss and dysgeusia.
Conclusions
The combination of CBZ and TMZ shows promising antitumor activity in patients with NENs. While tolerability appears to be an issue, the relatively high rate of toxicities observed in this study should be weighted against the characteristics of a heavily pretreated patient population.
Clinical trial identification
EudraCT 2020-001898-78.
Editorial acknowledgement
Legal entity responsible for the study
Istituto Nazionale Tumori IRCCS G. Pascale of Naples.
Funding
Ipsen.
Disclosure
C. von Arx: Financial Interests, Personal, Advisory Board, Receipt of consultation fees, Participation in a company sponsored speaker’s bureau: AstraZeneca; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Pierre-Fabre, Gentili, Lilly, Novartis, Ipsen; Financial Interests, Personal, Other, Conference Fee and travel grant: Organon; Financial Interests, Personal, Conference fee and travel grant: AAA. All other authors have declared no conflicts of interest.
Resources from the same session
1197P - Somatostatin analogs or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors
Presenter: Maria Grazia Maratta
Session: Poster session 13
1198P - Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings
Presenter: Jonathan Strosberg
Session: Poster session 13
1199P - MAVERIC: Phase II randomized study of everolimus as maintenance therapy for metastatic neuroendocrine neoplasms (mNEN) with pulmonary or gastroenteropancreatic (GEP) origin. Results on behalf of the GOIRC
Presenter: Lorenzo Antonuzzo
Session: Poster session 13
1201P - Evaluation of efficacy TEMCAP regiment as first-line or further line therapy in patients with advanced, unresectable, progressive GEP-NET. Real-world data
Presenter: Agnieszka Kolasinska-Cwikla
Session: Poster session 13
1202P - Final analysis of TENEC trial: A phase II trial of temozolomide (TMZ) as second-line treatment for advanced neuroendocrine carcinomas (NEC) in patients (pts) with a poor performance status (PS)
Presenter: Claudia von Arx
Session: Poster session 13